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Abstract
Background: Dextromethorphan is a safe, effective cough suppressant, available without a prescription in the
United States since 1958. Due to a perceived prevalence of abuse of dextromethorphan by teens, in 2007 the Drug
Enforcement Administration requested the Food and Drug Administration evaluate whether dextromethorphan
should be recommended for scheduling under the Controlled Substances Act. The Food and Drug Administration
held an Advisory Committee meeting in 2010 to provide a scientific and medical evaluation of dextromethorphan
and its abuse potential.
Discussion: To address reports of abuse, particularly by teens in the United States, the Consumer Healthcare Products
Association initiated an abuse mitigation plan in 2010 with specific goals related to awareness of the behavior,
perception of risk, social disapproval, and access to the products. In identifying abuse interventions, experts acknowledge
that substance abuse among teens is a highly complex behavior and indicate that the best course of action is to address
prevention by focusing on the factors that impact teen behavior.
Conclusion: It is noteworthy that the annual prevalence of over-the-counter cough medicine abuse has sharply
decreased since 2010. While a true cause-and-effect relationship cannot be assured, the Consumer Healthcare
Products Association and its member companies believe that the increased awareness of the issue since the 2010
Food and Drug Administration Advisory Committee meeting, and the subsequent implementation of a well-delivered
and targeted abuse mitigation plan that addressed the levers influencing teen decisions is contributing to the
observed reduction in abuse. During the period of 2010–2015, reported abuse of dextromethorphan by 8th, 10th, and
12th graders decreased 35 %. The authors believe this reduction supports the view of the Consumer Healthcare
Products Association at the outset of the abuse mitigation plan effort and today: Controlled substance scheduling or
prescription requirements would result in a reduction in the legitimate use of this medicine that has benefits that far
outweigh its risks. Instead, there are more targeted, more effective, and less disruptive interventions to address
dextromethorphan abuse.
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Background
Dextromethorphan is a safe, effective cough suppressant,
available without a prescription in the United States
since 1958. Due to a perceived prevalence of abuse of
dextromethorphan by teens, the Drug Enforcement
Administration requested the Food and Drug Adminis-
tration evaluate whether dextromethorphan should be
recommended for scheduling under the Controlled
Substances Act in 2007, and the Food and Drug Ad-
ministration held an Advisory Committee meeting in
2010 to provide a scientific and medical evaluation of
dextromethorphan and its abuse potential.
Main text
Overview of dextromethorphan (DXM)
Dextromethorphan (DXM) is a safe, cough suppressant
with a long history of nonprescription or over-the-counter
(OTC) use in the U.S. and many other countries. DXM
was approved by the U.S. Food and Drug Administration
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(FDA) as an OTC antitussive in 1958. In the 1970s, FDA
reviewed the available safety and efficacy data on DXM,
concluding that the drug was generally recognized as safe
and effective [1, 2]. While there were reports of abuse, a
review panel concluded “because of its low order of tox-
icity, it is probably the safest antitussive presently avail-
able” [1]. Millions of Americans have and continue to rely
on this accessible medicine; according to market research
firm IRI, DXM-containing OTC medicines comprise 85 to
90 % of all medicines containing a cough suppressant sold
in the U.S., and approximately 235 million packages of
DXM-containing OTC medicines were purchased in the
last year.
Acute cough is very prevalent, and multiple studies have
demonstrated that a majority of Americans self-medicate
for cough and the common cold [3]. People’s daily routines
are significantly impaired when they suffer from acute
cough, as symptoms create a burden and an economic
impact in terms of lost work days, school absenteeism,
and reduced work productivity [4, 5]. Access to OTCs,
like DXM, enables consumers to take appropriate con-
trol of their own healthcare and provides demonstrated
economic value to the healthcare system [6].
DXM is a centrally acting cough suppressant. It is be-
lieved to suppress cough by altering the threshold for
cough initiation through effects in the medulla oblongata
[7]. While its pharmacology is not completely understood,
DXM has been shown to bind to receptors implicated
in the cough response, including the sigma-1 receptors
and N-methyl-D-aspartate (NMDA) receptors. Although
DXM is an NMDA antagonist, it differs biochemically
from high-affinity antagonists such as phencyclidine and
dizocilpine [8]. DXM continues to be studied widely in
combination with other active pharmaceutical ingredients,
including for neurological conditions such as pseudobul-
bar effect and Rett syndrome [9, 10].
Although structurally similar to other morphine de-
rivatives, DXM is a non-narcotic cough suppressant
since it is devoid of morphine-like effects [11]. How-
ever, at high doses DXM can exert mixed clinical psy-
choactive effects which play a role in its non-medical
abuse, eliciting both euphoria and dysphoria, distorted vis-
ual perceptions, loss of motor coordination, dissociative
sedation, nausea, and vomiting [12]. Qualitative research
among substance abusers shows little recurring abuse of
DXM [11, 13, 14].
In 2006, the National Institute of Drug Abuse (NIDA)
funded Monitoring the Future survey showed abuse of
DXM-containing OTC cough medicine was concentrated
among teens and, to a lesser degree, young adults: 5.4 % of
8th, 10th, and 12th grade students reported non-medical
use of OTC cough medicine in the past year [15]. For
comparison, the survey reported that 22 % used marijuana
and 50.7 % used alcohol in the previous year [15].
Based on a perceived risk of increasing prevalence of
abuse among teens and despite the longstanding docu-
mented safety and benefit of DXM, the Drug Enforcement
Administration (DEA) in 2007 requested that FDA evalu-
ate whether DXM should be recommended for scheduling
under the Controlled Substances Act [16]. Subsequently,
FDA held an Advisory Committee meeting in September
2010 to provide a scientific and medical evaluation of
DXM and its abuse potential. To prepare for this meeting,
the Consumer Healthcare Products Association (CHPA),
representing the manufacturers of OTC medicines in the
U.S., reviewed the abuse of DXM. The review was based
on over 50 years of marketing experience; consultation
with experts; the totality of a review of pharmacology, pre-
clinical, and clinical study data; the prevalence of reported
abuse from national, government-sponsored surveys; a
review of outcomes databases; and the benefits and
risks of DXM to public health [12].
Industry and prevention expert abuse mitigation plan
Though these medicines provide relief to millions of
Americans annually safely and effectively, the limited
reports of abuse associated with DXM must also be ad-
dressed to maintain consumers’ safety. To directly address
these reports, as early as 2003 CHPA began developing
educational interventions against abuse [12]. By 2010, it
was not clear whether these interventions were sufficient,
at which point CHPA formalized its abuse interventions
through the development of an abuse mitigation plan with
participation from companies in the OTC industry and
leading abuse prevention experts. In identifying cough
medicine abuse interventions, experts acknowledge that
substance abuse among teens is a highly complex behavior
and indicate that the best course of action is to address
prevention by focusing on the factors that impact teen be-
havior. Literature points to a number of key factors lead-
ing to the prevalence of substance abuse among teenagers,
including low parental awareness, low teen perception of
risk, low perception of social disapproval, and ready avail-
ability [12]. Therefore, CHPA made a commitment to try
to reduce initiation of the behavior by delivering against
the following goals, initially set out at the 2010 FDA
Advisory Committee meeting, over a 3-year period:
– increase teen perception of risk by highlighting the
physical risks of abuse;
– increase teen perception of social disapproval by
emphasizing peer’s disapproval of abuse behavior
and demonstrating that non-abuse is the norm;
– raise awareness of DXM abuse and risks among
parents, caregivers, and teen-influencers; and
– limit teen access to DXM by increasing parental
safeguarding and monitoring of DXM-containing
medicines in the home and by advocating for
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legislation to establish a sales age restriction and
prohibit the sale of bulk, unfinished DXM to parties
not registered with FDA.
CHPA tracks the attitudes and behaviors of teens and
parents annually via sponsored qualitative and quantitative
research and available national survey data. In addition,
CHPA relies on the expertise and guidance of those with
demonstrated effectiveness in reducing drug abuse, such as
the Partnership for Drug-Free Kids (the Partnership) [17],
to develop plans that will best distribute the messages.
For example, a key strategy advocated by the Partner-
ship and implemented in components of the CHPA pro-
gram was to specifically target those teens most at risk
for abuse behavior. This was feasible using an Internet-
based outreach plan since data showed that teens actively
go online to search for information on how to abuse
DXM and to discuss the experience via social media. As
OTC cough medicine abuse is not widespread among the
teen population, this targeted approach also reduced the
potential unintended consequence of increasing interest
among non-abusers.
Thus, a portfolio of “bait-and-switch” YouTube videos,
Facebook and mobile app experiences, teen testimonial
videos, and a content-rich website was created in a teen
“voice.” All creative elements and messages were tested
with our target teen audiences prior to launch to ensure
maximum impact and to reduce potential unintended
consequences. The authenticity of these messages is
intended to discourage teens from abusing DXM with-
out turning them off from listening. Starting in 2012,
this content was selectively seeded across the Internet
where there was a high probability that potential teen
abusers would be exposed.
Regarding program components that target parents,
caregivers, and teen-influencers, CHPA has been educat-
ing on the issue since 2003. Following the trend toward
online engagement, the Stop Medicine Abuse campaign
now connects with parents and caregivers via online com-
munities in addition to local groups familiar to parents in-
cluding the Community Anti-Drug Coalitions of America,
the National School Nurses Association, and other trusted
sources. Contrary to the relatively small intended teen tar-
get audience, this target audience is the general parent
and caregiver populations. The program’s goal is to spread
awareness of the potential for abuse and encourage par-
ents and caregivers to take the steps necessary to prevent
it. The conversation between a parent and their child is
critical, as teens are up to 50 % less likely to use drugs if
they learn about the risks from their parents [18].
In addition, beginning in 2008, with expansion through
2010, CHPA member companies placed an icon on
packages of DXM sold in the U.S. alerting parents and
caregivers to the issue and directing them to StopMedi-
cineAbuse.org. There, they can learn about DXM abuse,
its side effects and warning signs, and tools on how to
prevent this behavior. CHPA estimates the icon is placed
on more than 235 million packages each year (Fig. 1).
Finally, access to DXM medicines can be limited by
parents in the home, and the CHPA campaign continues
to actively promote the safe storage and monitoring of
DXM-containing medicines. Further, the CHPA program
supports national and state legislation to limit minors’
access to the medicines by requiring that consumers be
at least 18 years old to purchase DXM, and by prohibiting
the sale of bulk, unfinished DXM to parties not registered
with FDA. With limited access, the prevalence rate should
decrease, as seen in youth tobacco use. The campaign to
Fig. 1 Icon placed on most packages containing DXM
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reduce youth smoking has included many tactics, but the
correlation between youth smoking and the sales restric-
tions to minors stands out. Since the 1992 Synar Act,
which required states to prohibit sales or distribution of
tobacco to minors, was implemented in 1996 by the Sub-
stance Abuse and Mental Health Service Administration
(SAMSHA) [19], the levels of past 30-day smoking have
fallen by about 80 % among 8th and 10th graders and by
more than 65 % among 12th graders [20]. Therefore,
CHPA is active in both direct lobbying and providing por-
tals for opinions of constituents to their representatives in
Congress or state legislatures to ensure teen access to
DXM is restricted.
Abuse mitigation plan results
The CHPA abuse mitigation campaign has focused on
addressing the levers that influence a teen’s decision, in-
cluding changing teen perceptions and attitudes toward
abuse behavior; raising awareness among parents, care-
givers, and influencers; and limiting teen access to these
medicines. The campaign has also collected data moni-
toring trends in each campaign element, as well as
measuring the overall annual prevalence of abuse.
Prevalence of abuse
Since 1975, the annual Monitoring the Future (MTF)
survey, conducted by the University of Michigan with
funding from the National Institutes of Health (NIH),
has surveyed 40,000 to 50,000 students from the 8th,
10th, and 12th grades in about 400 secondary schools
throughout the U.S. In 2006, the MTF survey added a
specific question on OTC cough medicine abuse; the re-
ported annual prevalence rates are shown in Table 1.
Since the 2010 FDA Advisory Committee meeting and
the subsequent start of the CHPA abuse mitigation
campaign, reports of abuse have decreased by approxi-
mately 35 % [15].
Teen perceptions and attitudes
Data on teen perceptions of risk and social disapproval
associated with cough medicine abuse were monitored
using data from the annual Partnership Attitude Track-
ing Survey (PATS) and from a CHPA-sponsored Online
Tracking Study conducted by Hall & Partners. PATS,
which surveyed teens in grades 9–12, assessed both their
perception of risk and social disapproval [21]. The data
(Table 2) shows that while there was little change in per-
ception of DXM abuse as a risky behavior, there was a
general disapproval of other teens using cough medi-
cines to get high among the surveyed teenagers since
2011.
The Hall & Partners Online Tracking Study [21] sur-
veyed 14- to 20-year-olds before and after exposure to
Internet content placed by the CHPA campaign. The
data (Table 3) strongly reveal after forced exposure to
campaign materials versus a baseline control group teens
are much more likely to understand the social and phys-
ical risks, including thinking the behavior is socially un-
acceptable and would cause nausea and vomiting.
Parental awareness and involvement
Data on parents’ awareness of and involvement in this
issue come from two sources: 1) a CHPA-sponsored on-
line survey conducted by David Binder Research in
2010, 2012, and 2013, and 2015 [21], and 2) the annual
PATS survey [21]. As seen in Table 4, these data show
nominal increases in parental monitoring and safeguard-
ing of cough medicine in their household. However, re-
sults from both studies indicate that only about half of
Table 1 Prevalence of Abuse: Monitoring The Future
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
8th Grade 4.2 % 4.0 % 3.6 % 3.8 % 3.2 % 2.7 % 3.0 % 2.9 % 2.0 % 1.6 %
10th Grade 5.3 % 5.4 % 5.3 % 6.0 % 5.1 % 5.5 % 4.7 % 4.3 % 3.7 % 3.3 %
12th Grade 6.9 % 5.8 % 5.5 % 5.9 % 6.6 % 5.3 % 5.6 % 5.0 % 4.1 % 4.6 %
Average 5.4 % 5.0 % 4.7 % 5.2 % 4.8 % 4.4 % 4.4 % 4.0 % 3.2 % 3.1 %
Table 2 Teen Attitude/Behavioral Changes: PATS Results
PATS (asked of teens) 2008 2009 2010 2011 2012 2013
Taking non-prescription cough or cold medicine to get high is risky
(agree strongly/somewhat)
85 % 80 % 78 % 80 % 79 % 75 %
Taking non-prescription cough/cold medicine to get high has risks,
including nausea and vomiting (agree strongly/somewhat)
N/A N/A N/A 88 % 88 % 86 %
Disapprove of others using non-prescription cough/cold products to
get high (strongly disapprove/disapprove)
N/A N/A N/A 81 % 86 % 90 %
Taking non-prescription cough/cold medicine to get high is something
cool kids do (agree strongly/somewhat)
N/A N/A N/A 29 % 36 % 26 %
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the surveyed parents are talking about cough medicine
abuse.
Access
While access to DXM-containing medicines can be lim-
ited by increased parental monitoring, legislative and
voluntary efforts to restrict access to those under
18 years of age continue. As of March 2016, ten states
(California, New York, Virginia, Washington, Arizona,
Louisiana, Kentucky, Tennessee, New Jersey, and Florida)
have enacted age-restriction laws that prevent consumers
under the age of 18 from purchasing products containing
DXM. Although bipartisan, bicameral legislation was intro-
duced in past Congresses, it has not yet passed. CHPA
continues to lobby for federal and additional state legisla-
tion. Voluntary efforts by more than 20 national and re-
gional retailers have also stopped selling to consumers
under 18. According to the market research firm IRI be-
tween legislative and voluntary efforts, 88–90 % of the
market does not sell dextromethorphan to those under 18.
There are limitations to the success of CHPA’s plan in
that the breadth of information on how to abuse OTC
cough medicine available on the Internet cannot be
controlled. As long as there is information available, in-
cluding dosage calculators and demonstration videos
available through Google, Yahoo!, YouTube, Facebook,
and elsewhere online, teens will always have the ability
to learn about the behavior.
Adverse event reporting system analysis
Another measure of the potential for abuse of DXM is
adverse events reported to the FDA Adverse Event (AE)
Reporting System database (FAERS). It is important to
note that these events have been reported in association
with DXM and do not prove that the drug was the
causative agent. To assess whether there were changes
in abuse-related serious adverse events associated with
DXM over the first 3 years of CHPA’s abuse mitigation
plan, CHPA commissioned a search of the FAERS data-
base (2010–2013) using terms related to abuse. The
search revealed a total of 56 adverse events in which
DXM was listed as a primary suspect drug, including 32
with an associated outcome of death. Twenty-seven of
these 32 reports included co-suspect drugs, including
opiates and stimulants, and 19 were from the “2011 An-
nual Report of the American Association of Poison Con-
trol Centers’ National Poison Data System (NPDS): 29th
Annual Report.” Apart from an abrupt increase in AEs
in the first quarter of 2013, which may have been driven
by the publication of the 2011 NPDS annual report, this
pattern was not sustained over the remaining quarters of
2013.
Table 3 Teen Attitude/Behavioral Changes: Hall & Partners Online Tracking Study
Hall & Partners Online Tracking Study (asked of teens) Benchmark (2013) After forced exposure (2015) Difference in % points between
forced exposure and benchmark
Please indicate how much you agree with the following statements about using non-prescription cough/cold medicine to get high
Causes nausea and can lead to vomiting 63 % 92 % +29
Don’t want to be seen as the kind of person who would do this 67 % 78 % +11
Will make me look bad in front of friends 54 % 72 % +18
Would you say the using non-prescription cough/cold medicine to get high is
Feel physically sick 38 % 62 % +24
Ashamed of 18 % 31 % +13
Socially unacceptable 12 % 35 % +23
Turns off friends 13 % 36 % +23
Table 4 Parental Awareness/Involvement: David Binder Research Results
David Binder Research (asked of adults) 2010 2011 2012 2013 2015
Q. Which, if any, of the following actions have you taken?
Monitored the amount of cough medicine in your household 31 % N/A 39 % 37 % 40 %
Take steps to safeguard safe storage 30 % N/A 38 % 33 % 44 %
Talked to your child about the dangers of cough medicine abuse 42 % N/A 46 % 47 % 45 %
PATS (asked of adults)
Had a conversation with teenager about using non-prescription cold or cough medicine to get high 58 % 57 % 67 % 59 % N/A
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Conclusions
The annual prevalence of OTC cough medicine abuse
has been decreasing since 2006 when the question first
appeared in Monitoring The Future and 3 years into
CHPA’s preliminary education efforts. Similarly, the
prevalence of abuse of a number of other substances has
gone down over the past 9 years. We note, however, that
since CHPA’s plan was presented at the 2010 FDA Advis-
ory Committee meeting, the rate of decrease, according to
MTF, appears accelerated. While a true cause-and-effect
relationship cannot be assured, the authors, CHPA, and
its member companies believe that the increased aware-
ness of the issue since the 2010 FDA Advisory Commit-
tee meeting and the subsequent implementation of a
well-delivered and targeted abuse mitigation plan that
addressed the levers influencing teen decisions may be
contributing to the observed reduction in abuse. Further
support for this conclusion is found in a review of
National Poison Data System intentional DXM abuse
cases from 2000 to 2010, where Wilson et al. concluded it
was likely a combination of legislative and educational ef-
forts including CHPA’s efforts prior to our announcement
of formal abuse mitigation plan goals and more compre-
hensive interventions that were responsible for what by
2010 was an observed plateau in DXM cases [22]. CHPA
and the authors also believes that to continue providing
cough symptom relief to those who require it, and because
the results of targeted abuse mitigation efforts seem
positive, this ingredient should remain accessible to con-
sumers over the counter. Finally, CHPA hopes this case
study on reducing substance abuse through targeted inter-
ventions can facilitate further discussion and provide learn-
ings on effective approaches to preventing substance
abuse, teen or otherwise.
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